A recent meta-analysis reported that BNP/NT-proBNP-guided heart failure pharmacotherapy resulted in significant reductions in mortality in patients under 75 years of age compared to specialist care alone (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.45–0.85) [37]. This evidence concerns the gene NPPB and heart failure.